| Name | CA-4948 |
|---|---|
| Synonyms |
IRAK4-IN-2
6'-Amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl][2,3'-bipyridine]-6-cboxamide IRAK4-IN-7, 10 mM in DMSO CA4948-Analog IRAK4-IN-7 ABC-type,lge B cell lymphoma,IRAK4,IRAK,lymphoma,DLBCL,IRAK4 IN 7,IL-1R associated kinase,non-Hodgkin,diffuse,IRAK-4-IN-7,Interleukin-1 rector associated kinase,Inhibitor,IRAK4IN7,inhibit IRAK4-IN-7 CA-4948 CA 4948;CA [2,3'-Bipyridine]-6-cboxamide, 6'-amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl] 6'-Amino-N-[2-(morpholin-4-yl)-[1,3]oxazolo[4,5-b]pyridin-6-yl]-[2,3'-bipyridine]-6-cboxamide IRAK4-IN-7 (CA4948 analog) 6'-Amino-N-(2-morpholinooxazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-cboxamide CA 4948, CA-4948, CA4948 N-(1-(6'-amino-[2,3'-bipyridin]-5-yl)vinyl)-2-morpholinooxazolo[4,5-c]pyridin-6-amine |
| Description | CA-4948 is a selective and potent IRAK4 inhibitor. |
|---|---|
| Related Catalog | |
| Target |
IRAK4[1] |
| In Vivo | CA-4948 is a selective and potent IRAK4 inhibitor which can be used as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. Furthermore, CA-4948 is previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models[1]. |
| References |
| Molecular Formula | C21H19N7O3 |
|---|---|
| Molecular Weight | 417.42 |
| Storage condition | -20℃ |